SCHEMBL7566154

SCHEMBL7566154

COc1ccccc1CNc1ccccc1Oc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.63
ALDH1A1 P00352 4/20 0.57
KDM4E B2RXH2 3/20 0.57
MAPT P10636 3/20 0.57
HPGD P15428 1/20 0.57
GAA P10253 2/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
CACNA1B Q00975 2/20 0.50
ACP1 P24666 1/20 0.49
KDM4C Q9H3R0 1/20 0.49
HIF1A Q16665 1/20 0.49
ATM Q13315 1/20 0.49
ASPH Q12797 1/20 0.48
KDM8 Q8N371 1/20 0.48
ABCB1 P08183 1/20 0.48
ABCG2 Q9UNQ0 1/20 0.48
POLB P06746 1/20 0.47
MAOA P21397 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11213118 0.90 L3MBTL1 (0.58) L3MBTL1ALDH1A1KDM4EMAPTHPGD
SCHEMBL14542280 0.88 ABCB1 (0.62) L3MBTL1ALDH1A1KDM4EMAPTHPGD
SCHEMBL7569661 0.87 APLNR (0.55) L3MBTL1ALDH1A1KDM4EMAPTHPGD
SCHEMBL7568812 0.87 MAPK8 (0.60) L3MBTL1ALDH1A1KDM4EMAPTHPGD
SCHEMBL7570776 0.85 MTNR1A (0.49) L3MBTL1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL7568020 0.84 CACNA1B (0.47) L3MBTL1ALDH1A1KDM4EMAPTHPGD
SCHEMBL244041 0.82 KDM1A (0.47) L3MBTL1ALDH1A1KDM4EMAPTHPGD
SCHEMBL14821593 0.81 CA12 (0.64) L3MBTL1ALDH1A1KDM4EMAPTGAA
SCHEMBL14542282 0.81 ALDH1A1 (0.57) L3MBTL1ALDH1A1MAPTCACNA1BKDM4C
SCHEMBL14542283 0.79 ABCB1 (0.58) ALDH1A1KDM4EGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6476056-B2 ANTIINFLAMMATORY AGENTS, PSYCHOLOGICAL DISORDERS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2002-11-05 US disclosed
EP-1004573-B1 ARYLOXYANILINE DERIVATIVES TAISHO PHARMACEUTICAL CO LTD (JP) 2002-10-30 EP disclosed
US-20020147191-A1 Aryloxyaniline derivatives NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-10-10 US disclosed
US-6333358-B1 AMIDE DERIVATIVES OF ANILINE AS ANTIDEPRESSANTS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2001-12-25 US disclosed
CN-1265642-A Aryloxyaniline derivatives TAISHO PHARMACEUTICAL CO LTD (JP) 2000-09-06 CN disclosed
EP-1004573-A1 ARYLOXYANILINE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD (JP) 2000-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147191-A1 Aryloxyaniline derivatives FPR2, ARG2, CYP11B2 L3MBTL1 3662/4885ALDH1A1 564/4885KDM4E 1695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.